We are live on
!
Find out more
Qube Research & Technologies (QRT) Portfolio holdings
AUM
$89.9B
1-Year Est. Return
20.22%
This Fund
S&P 500
This Quarter
Est. Return
+6.9%
1 Year Est. Return
+20.22%
3 Year Est. Return
+42.42%
5 Year Est. Return
+23.97%
10 Year Est. Return
–
AUM
$98.4B
AUM Growth
+$12.2B
(+14%)
Cap. Flow
+$4.67B
Cap. Flow
% of AUM
4.75%
Top 10 Holdings %
Top 10 Hldgs %
7.81%
Holding
4,101
New
656
Increased
1,629
Reduced
1,101
Closed
596
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$486M |
| 2 |
Apple
AAPL
|
+$485M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$479M |
| 4 |
Uber
UBER
|
+$376M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$363M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$1.02B |
| 2 |
Meta Platforms (Facebook)
META
|
+$675M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$545M |
| 4 |
Microsoft
MSFT
|
+$482M |
| 5 |
Applied Materials
AMAT
|
+$404M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.24% |
| 2 | Financials | 10.53% |
| 3 | Industrials | 10.31% |
| 4 | Healthcare | 10.01% |
| 5 | Consumer Discretionary | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3076
PUT
Alaska Air
ALK
$5.15B
| $79.2K | ﹤0.01% |
+1,600
| New | +$77.7K |
|
3077
Invesco Dorsey Wright Technology Momentum ETF
PTF
$632M
| $79K | ﹤0.01% |
1,157
+1,137
| +5,685% | +$70.1K |
|
3078
Roadzen
RDZN
$101M
| $78.5K | ﹤0.01% |
+80,075
| New | +$80.2K |
|
|
TRUE
3079
DELISTED
TrueCar
TRUE
| $78.3K | ﹤0.01% |
41,205
-155,165
| -79% | -$237K |
|
3080
Commercial Vehicle Group
CVGI
$157M
| $77.9K | ﹤0.01% |
+46,928
| New | +$57K |
|
3081
PUT
Bilibili
BILI
$7.18B
| $77.2K | ﹤0.01% |
3,600
+3,000
| +500% | +$55.2K |
|
3082
iShares Global Tech ETF
IXN
$8.7B
| $76.9K | ﹤0.01% |
833
-12,251
| -94% | -$993K |
|
3083
Dimensional US Core Equity Market ETF
DFAU
$12.3B
| $74.4K | ﹤0.01% |
1,757
-1,689
| -49% | -$66.2K |
|
|
BTM
3084
DELISTED
Bitcoin Depot
BTM
| $74.2K | ﹤0.01% |
+2,092
| New | +$44.4K |
|
3085
iShares MSCI Emerging Markets Asia ETF
EEMA
$827M
| $73.2K | ﹤0.01% |
887
+266
| +43% | +$20.3K |
|
3086
DLH Holdings
DLHC
$73.8M
| $73.2K | ﹤0.01% |
+12,533
| New | +$56.6K |
|
3087
Dimensional US Marketwide Value ETF
DFUV
$15.4B
| $72.8K | ﹤0.01% |
1,721
-2,912
| -63% | -$117K |
|
3088
CuriosityStream
CURI
$139M
| $72.6K | ﹤0.01% |
12,888
-35,978
| -74% | -$165K |
|
3089
iShares International Dividend Growth ETF
IGRO
$1.27B
| $72.5K | ﹤0.01% |
+919
| New | +$69.5K |
|
3090
State Street SPDR MSCI ACWI ex-US ETF
CWI
$2.74B
| $71.7K | ﹤0.01% |
2,196
-2,473
| -53% | -$76K |
|
3091
Schwab US REIT ETF
SCHH
$11.7B
| $71.5K | ﹤0.01% |
3,381
+2,433
| +257% | +$51K |
|
3092
PUT
Nasdaq
NDAQ
$51.5B
| $71.5K | ﹤0.01% |
800
+300
| +60% | +$23.9K |
|
3093
VanEck Preferred Securities ex Financials ETF
PFXF
$2.39B
| $70.4K | ﹤0.01% |
4,111
+1,491
| +57% | +$24.7K |
|
3094
Fidelity Enhanced Large Cap Growth ETF
FELG
$5.44B
| $70K | ﹤0.01% |
1,891
-1,253
| -40% | -$41.8K |
|
3095
Context Therapeutics
CNTX
$56.4M
| $70K | ﹤0.01% |
106,779
-67,530
| -39% | -$48.6K |
|
3096
Actinium Pharmaceuticals
ATNM
$27M
| $69.9K | ﹤0.01% |
+49,932
| New | +$74.7K |
|
3097
Nuveen ESG Mid-Cap Growth ETF
NUMG
$343M
| $68.4K | ﹤0.01% |
1,412
-236
| -14% | -$10.6K |
|
3098
T. Rowe Price US Equity Research ETF
TSPA
$4.1B
| $67.1K | ﹤0.01% |
+1,726
| New | +$62.1K |
|
3099
Acumen Pharmaceuticals
ABOS
$154M
| $66.8K | ﹤0.01% |
57,559
+35,424
| +160% | +$38.1K |
|
3100
Telos
TLS
$337M
| $66.7K | ﹤0.01% |
+21,048
| New | +$54.7K |
|
Similar funds
Qube Research & Technologies (QRT)'s Q2 2025 Portfolio in Review
As of Q2 2025, Qube Research & Technologies (QRT) held 4,101 positions worth $98.4B, up 14% from $86.2B the previous quarter. Its ten largest holdings account for 7.8% of the portfolio.
Qube Research & Technologies (QRT) deployed $4.67B of net new capital in Q2 2025, opening 656 new positions and adding to 1,629 existing holdings. Its largest new stake was Bristol-Myers Squibb: 9,752,683 shares worth $451M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 15% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $675M trimmed.
- Qube Research & Technologies (QRT)'s largest Q2 2025 buy was Bristol-Myers Squibb: 9,752,683 shares worth $451M.
- Qube Research & Technologies (QRT) added most to Thermo Fisher Scientific in Q2 2025, an estimated $486M increase.
- Qube Research & Technologies (QRT)'s biggest Q2 2025 reduction was Meta Platforms (Facebook), cutting an estimated $675M.
- Qube Research & Technologies (QRT) fully exited Broadcom in Q2 2025, selling an estimated $1.02B.
- Qube Research & Technologies (QRT)'s ten largest holdings make up 7.8% of its $98.4B portfolio in Q2 2025.
- Qube Research & Technologies (QRT) opened 656 new positions and closed 596 in Q2 2025.
- Qube Research & Technologies (QRT)'s portfolio value rose 14% quarter-over-quarter to $98.4B.
Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2025, filed 14 Aug 2025.